Cargando…
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
BACKGROUND: To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy. METHODS: Nine hundred twenty-four AOA patients treated at 28 Spanish teaching...
Autores principales: | Custodio, A, Carmona-Bayonas, A, Jiménez-Fonseca, P, Sánchez, M L, Viudez, A, Hernández, R, Cano, J M, Echavarria, I, Pericay, C, Mangas, M, Visa, L, Buxo, E, García, T, Rodríguez Palomo, A, Álvarez Manceñido, F, Lacalle, A, Macias, I, Azkarate, A, Ramchandani, A, Fernández Montes, A, López, C, Longo, F, Sánchez Bayona, R, Limón, M L, Díaz-Serrano, A, Hurtado, A, Madero, R, Gómez, C, Gallego, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518851/ https://www.ncbi.nlm.nih.gov/pubmed/28463962 http://dx.doi.org/10.1038/bjc.2017.122 |
Ejemplares similares
-
Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
por: Jiménez Fonseca, Paula, et al.
Publicado: (2017) -
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
por: Plazas, J. Gallego, et al.
Publicado: (2022) -
Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)
por: Puhr, H.C., et al.
Publicado: (2022) -
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
por: Noble, F, et al.
Publicado: (2017) -
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
por: Jimenez-Fonseca, Paula, et al.
Publicado: (2023)